StockData
Nephros Inc logo

Nephros Inc (NEPH) shareholders

NEPHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3020% below fair value
$2.90−0.10 (-3.33%)

Close on Nov 17, 2026Market cap $31.49MP/E 18.1Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
48.9%
5M of 11M shares
Institutional holders
33
7 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Charles E. Davidson
Joint filing with CD Holding Company, LLC (5.68%)
616,9455.68%13G (passive)Sep 14, 2026
Topline Capital Management, LLC
Joint filing with Collin McBirney (5.60%), Topline Capital Partners, LP (5.60%)
595,3345.60%13G (passive)Aug 4, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NEPHValueChange% of portfolio
Wexford Capital LP3,600,55233.15%$12.85M–1.64%
Topline Capital Management, LLC535,6984.93%$1.91M−46,2690.50%
Vanguard Capital Management LLC198,6431.83%$709.16K–0.00%
Morgan Stanley128,9151.19%$460.23K+18,0000.00%
Cornerstone Capital, Inc.128,7001.19%$459.46K–0.04%
Bard Associates Inc118,0031.09%$421.27K−3,1990.09%
Renaissance Technologies LLC77,5040.71%$276.69K−21,8960.00%
Geode Capital Management, LLC70,2630.65%$250.92K−2,6620.00%
Mesirow Financial Investment Management, Inc.60,0000.55%$214.20K−60,0000.00%
HighTower Advisors, LLC59,7100.55%$213.17K–0.00%
Navellier & Associates Inc53,4790.49%$190.92K+34,3530.02%
Essex Investment Management Co LLC38,9270.36%$138.97K−570.02%
Vanguard Fiduciary Trust Co36,9010.34%$131.74K–0.00%
Blair William & Co/Il36,2490.33%$129.41K–0.00%
Citadel Advisors LLC29,0440.27%$103.69K+8,1560.00%
Dimensional Fund Advisors LP22,1640.20%$79.13K+1,4190.00%
BlackRock, Inc.18,8220.17%$67.20KNew0.00%
De Lisle Partners LLP17,4000.16%$62.12K−7,6000.01%
Northern Trust Corp16,7060.15%$59.64K+5,8780.00%
State Street Corp15,6980.14%$56.04K–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026335M48.9%7 / 79 / 10M0M
Q1 2026275M49.4%3 / 69 / 101M0M
Q4 2025355M48.8%14 / 115 / 30M0M
Q3 2025245M46.2%4 / 49 / 10M0M
Q2 2025215M44.7%4 / 85 / 10M0M
Q1 2025185M43.0%1 / 55 / 10M0M
Q4 2024185M43.4%3 / 27 / 20M0M
Q3 2024174M39.5%0 / 56 / 20M0M
Q2 2024194M39.9%4 / 56 / 30M0M
Q1 2024184M39.4%3 / 83 / 30M0M
Q4 2023184M40.2%4 / 62 / 00M0M
Q3 2023144M39.5%1 / 33 / 30M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

15 funds held NEPH in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NEPHValue% of fundAs of
Vanguard Total Stock Market Index Fund130,9011.21%$467.32K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund67,7420.62%$241.84K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund33,7070.31%$123.37K0.00%May 31, 2026
iShares Micro-Cap ETF17,7420.16%$63.34K0.00%Jun 30, 2026
Fidelity Total Market Index Fund11,5710.11%$42.35K0.00%May 31, 2026
Fidelity Series Total Market Index Fund9,5280.09%$34.87K0.00%May 31, 2026
Dimensional U.S. Core Equity 2 ETF4,8110.04%$16.31K0.00%Jul 31, 2026
U.S. Sustainability Core 1 Portfolio3,3370.03%$11.31K0.00%Jul 31, 2026
Fidelity Nasdaq Composite Index Fund3,0850.03%$11.29K0.00%May 31, 2026
U.S. Core Equity 2 Portfolio2,7250.03%$9.24K0.00%Jul 31, 2026
Dimensional US Core Equity 1 ETF2,4620.02%$8.35K0.00%Jul 31, 2026
U.S. Core Equity 1 Portfolio2,3330.02%$7.91K0.00%Jul 31, 2026
U.S. Social Core Equity 2 Portfolio2,3320.02%$7.91K0.00%Jul 31, 2026
U.S. Vector Equity Portfolio1,4190.01%$4.81K0.00%Jul 31, 2026
1290 VT Micro Cap Portfolio1,0800.01%$3.86K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Robert R. Banks Jr.President and CEO190,0001.75%Mar 25, 2026
Judy KrandelChief Financial Officer68,8610.63%Mar 25, 2026
Arthur H. AmronDirector187,6831.73%Nov 12, 2026
Oliver J. SpandowDirector126,7971.17%Nov 12, 2026
Holdings LLC AmronDirector187,0051.72%Sep 16, 2026
Lisa Marie NettisDirector1,6220.01%Nov 13, 2025
Alisa LaskDirector48,6290.45%Jan 3, 2025
Joseph Michael HarrisDirector17,6930.16%Jan 3, 2025
Charles E. Davidson10% owner3,608,66733.23%Sep 16, 2026
GP LLC Wexford10% owner245,4372.26%Sep 16, 2026
Capital Lp Wexford10% owner3,650,52933.61%Sep 16, 2026
Joseph Jacobs10% owner30,047,742276.68%Sep 16, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Oliver J. Spandow
Director
Nov 9, 2026Award+3,916––126,797
Arthur H. Amron
Director
Nov 9, 2026Award+3,514––162,137
Holdings LLC Amron
Director
Sep 14, 2026Other+22,710$3.95$89.70K25,546
Holdings LLC Amron
Director
Sep 14, 2026Other+17,749––158,623
Holdings LLC Amron
Director
Sep 14, 2026Other+2,836––2,836
GP LLC Wexford
10% owner
Sep 14, 2026Other−3,355,111––189,377
GP LLC Wexford
10% owner
Sep 14, 2026Other−22,710$3.95$89.70K166,667
Joseph Jacobs
10% owner
Aug 18, 2026Option exercise+812$3.60$2.92K56,872
Arthur H. Amron
Director
Aug 12, 2026Award+2,418––140,874
Arthur H. Amron
Director
May 11, 2026Award+3,574––138,456
Judy Krandel
Chief Financial Officer
Mar 23, 2026Option exercise+68,861$1.71$117.75K68,861
Robert R. Banks Jr.
President and CEO
Mar 23, 2026Option exercise+120,000$1.44$172.80K190,000
Arthur H. Amron
Director
Mar 16, 2026Award+3,610––134,882
Lisa Marie Nettis
Director
Nov 10, 2025Award+1,622––1,622
Arthur H. Amron
Director
Nov 10, 2025Award+5,391––131,272
Oliver J. Spandow
Director
Nov 10, 2025Award+8,036––122,881
Arthur H. Amron
Director
Jan 1, 2025Award+22,418––125,881
Oliver J. Spandow
Director
Jan 1, 2025Award+33,241––114,845
Arthur H. Amron
Director
May 30, 2024Buy+3,000$2.24$6.72K103,463
Arthur H. Amron
Director
May 28, 2024Buy+2,000$2.22$4.44K100,463
Robert R. Banks Jr.
President and CEO, Director
May 16, 2024Buy+50,000$2.24$112.00K70,000
Arthur H. Amron
Director
Mar 13, 2024Other+91,463––98,463
GP LLC Wexford
10% owner
Mar 13, 2024Other−91,463––56,060
Arthur H. Amron
Director
Mar 12, 2024Buy+7,000$2.45$17.15K7,000
Oliver J. Spandow
Director
Dec 13, 2023Award+14,294––81,604
Arthur H. Amron
Director
Dec 13, 2023Award+9,291––9,291
Joseph Michael Harris
Director
Dec 13, 2023Award+9,291––17,693
Alisa Lask
Director
Dec 13, 2023Award+9,291––48,629
Robert R. Banks Jr.
President and CEO, Director
Dec 7, 2023Buy+18,000$2.20$39.60K20,000
Robert R. Banks Jr.
President and CEO, Director
Aug 15, 2023Buy+1,901$1.69$3.21K2,000
Robert R. Banks Jr.
President and CEO, Director
Aug 14, 2023Buy+99$1.50$14999
Oliver J. Spandow
Director
Jan 5, 2023Award+42,481––67,310
Tom Gwydir
Director
Jan 5, 2023Award+27,613––43,226
Alisa Lask
Director
Jan 5, 2023Award+27,613––39,338
Joseph Michael Harris
Director
Jan 5, 2023Award+8,402––8,402
Arthur H. Amron
Director
Jan 5, 2023Award+27,613––27,613
Andrew Astor
President, CEO & CFO, Director
Mar 5, 2022Option exercise+14,815$2.70$40.00K92,773
Wesley S. Lobo
Chief Marketing Officer
Feb 16, 2022Tax withholding−6,389$4.80$30.67K35,168
Tom Gwydir
Director
Dec 14, 2021Award+4,582––15,613
Arthur H. Amron
Director
Dec 14, 2021Award+4,582––4,582
Alisa Lask
Director
Dec 14, 2021Award+4,582––11,725
Oliver J. Spandow
Director
Dec 14, 2021Award+5,429––24,829
Wesley S. Lobo
Chief Marketing Officer
Aug 20, 2021Buy+1,000$7.92$7.92K41,557
Tom Gwydir
Director
Aug 18, 2021Buy+5,000$7.64$38.20K11,031
Andrew Astor
President & CEO, Director
Aug 18, 2021Buy+2,500$7.77$19.43K77,958
Andrew Astor
President & CEO, Director
Aug 17, 2021Buy+2,500$7.67$19.18K75,458
Capital Lp Wexford
Director, 10% owner
Jun 1, 2021Option exercise+66,667$2.70$180.00K3,544,492
Daron Evans
CEO Specialty Renal Products
May 27, 2021Tax withholding−349$2.70$9428,669
Daron Evans
CEO Specialty Renal Products
May 27, 2021Tax withholding−349$2.70$9428,947
Daron Evans
CEO of Specialty Renal Product
May 24, 2021Option exercise+1,111$2.70$3.00K9,018
Daron Evans
CEO of Specialty Renal Product
May 24, 2021Option exercise+1,111$2.70$3.00K9,296
Wesley S. Lobo
Chief Marketing Officer
Feb 16, 2021Award+40,557––40,557
GP LLC Wexford
Director, 10% owner
Jan 27, 2021Option exercise+2,956$4.14$12.24K97,795
GP LLC Wexford
Director, 10% owner
Jan 27, 2021Option exercise+3,765$3.60$13.55K101,560
GP LLC Wexford
Director, 10% owner
Jan 27, 2021Option exercise+4,477$4.50$20.15K106,037
GP LLC Wexford
Director, 10% owner
Jan 27, 2021Option exercise+3,556$4.59$16.32K94,839
Arthur H. Amron
Director
Jan 6, 2021Award+3,666––3,666
Alisa Lask
Director
Jan 6, 2021Award+3,666––7,143
Malcolm C. Persen
Director
Jan 6, 2021Award+5,921––48,774
Tom Gwydir
Director
Jan 6, 2021Award+3,666––6,031

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.12%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-22.9%
From 0M shares
Short volume, 20 days
32.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nephros's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,509 shares on Aug 31, 2026 over the last 90 days.

See a number that looks wrong?